Last reviewed 2026-05-30 · How we verify

SLI-F06

Scarless Laboratories, Inc. · Phase 2 active Small molecule ✓ Verified May 2026

SLI-F06 is a Small molecule drug developed by Scarless Laboratories, Inc.. It is currently in Phase 2 development. Also known as: F06-C40.

SLI-F06 is a treatment being studied for its potential to improve scar appearance. A randomized, within-subject controlled study (NCT05501327) is investigating the dose regimen of SLI-F06 in healthy volunteers.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SLI-F06
Also known as	F06-C40
Sponsor	Scarless Laboratories, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Regimen Study of SLI-F06 in Healthy Volunteers (PHASE2)
Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SLI-F06 CI brief — competitive landscape report
SLI-F06 updates RSS · CI watch RSS
Scarless Laboratories, Inc. portfolio CI

Frequently asked questions about SLI-F06

What is SLI-F06?

SLI-F06 is a Small molecule drug developed by Scarless Laboratories, Inc..

Who makes SLI-F06?

SLI-F06 is developed by Scarless Laboratories, Inc. (see full Scarless Laboratories, Inc. pipeline at /company/scarless-laboratories-inc).

Is SLI-F06 also known as anything else?

SLI-F06 is also known as F06-C40.

What development phase is SLI-F06 in?

SLI-F06 is in Phase 2.

Manufacturer: Scarless Laboratories, Inc. — full pipeline
Also known as: F06-C40

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing